MichaelHolersMD

PubMed

• 10 citations
  A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury.
  C. Li, Kunal Patel, Zhenxiao Tu, Xiaofeng Yang, Liudmila Kulik
  American Journal of Transplantation. 2021-02-26
• 8 citations
  Elevated plasma complement components in facioscapulohumeral dystrophy.
  Chao-Jen Wong, Leo Wang, V Michael Holers, Ashley Frazer-Abel, Silvère M van der Maarel
  Human Molecular Genetics. 2022-06-04
• 6 citations
  Relationship Between a Vitamin D Genetic Risk Score and Autoantibodies Among First-Degree Relatives of Probands With Rheumatoid Arthritis and Systemic Lupus Erythemato...
  Lauren A Vanderlinden, Elizabeth A Bemis, Jennifer Seifert, Joel M Guthridge, Kendra A Young
  Frontiers in Immunology. 2022-01-01

Journal Articles

• MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease  
  Jay H Ryu, Deborah Assayag, Marvin I Schwarz, Paul Wolters, Andrew Gross, Ivan O Rosas, Aryeh Fischer, Michael Holers, Eric L Matteson, Timothy B Niewold, The New England Journal of Medicine
• Annexin A2 enhances complement activation by inhibiting factor H  
  Renner, B., Tong, H.H., Laskowski, J., Jonscher, K., Goetz, L., Woolaver, R., Hannan J., Li, Y.X., Hourcade, D., Pickering, M.C., Holers, V.M., and Thurman, J.M., J. Immunol. , 1/1/2016
• Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis:...  
  Gan, R.W., Young, K.A., Zerbe, G.O., Demoruelle, M.K., Weisman, M.H., Buckner, J.H., Gregersen, P.K., Mikuls, T.R., O'Dell, J.R., Keating, R.M., Clare-Salzler, M.J., D..., Rheumatology, 1/1/2016
• Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury  
  Laskowski, J., Renner, B., Le Quintrec, M., Panzer, S., Hannan, J.P., Ljubanovic, D., Ruseva, M.M., Borza, D.B., Antonioli, A.H., Pickering, M.C., Holers, V.M., and Th..., Kidney Int., 1/1/2016
• IgA Plasmablasts are elevated in subjects at risk for future rheumatoid arthritis  
  Kinslow, J.D., Blum, L.K., Deane, KD., Demoruelle, M.K., Okamoto, Y., Parish, M., Kongpachith, S., Lahey, L.J., Norris, J.M., Robinson, W.H., and Holers, V.M., Arth. Rheum., 1/1/2016
• Activation of human complement system by dextran-coated iron oxide nanoparticles is not affected by dextran/Fe ratio, hydroxyl modifications, and crosslinking  
  Wang, G,, Chen, F., Banda, N.K., Holers, V.M., Wu, L., Moghimi, S.M., and Simberg, D., Front. Immunol., 1/1/2016
• A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22  
  Chang, H.-H., Liu, G.-Y., Dwivedi, N., Sun, B., Okamoto, Y., Kinslow, J.D., Deane, K.D., Demoruelle, M.K., Norris, J.M., Thompson, P.R., Sparks, J.A.,  Rao, D.A, Karls..., JCI Insight, 1/1/2016
• Mapping the complement factor H-related protein 1 (CFHR1):C3b/C3d interactions  
  Hannan, J.P., Laskowski, J., Thurman, J.M., Hageman, G.S.,  and Holers, V.M., PLoS One, 1/1/2016
• Mannan-binding lectin-associated serine protease 1/3 cleavage of pro-factor D into factor D in vivo and attenuation of collagen antibody-induced arthritis through thei...  
  Banda, N.K., Acharya, S., Scheinman, R.I., Mehta, G., Coulombe, M., Takahashi, M., Sekine, H., Thiel, S., Fujita, T., and Holers, V.M., J. Immunol., 1/1/2016
• New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities  
  Holers V.M., Tomlinson, S., Kulik, L., Atkinson, C., Rohrer, B., Banda, N., and Thurman, J.M., Semin. Immunol, 1/1/2016
• Targeting mechanisms at sites of complement activation for imaging and therapy  
  Holers, V.M., Immunobiology, 1/1/2016
• Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury  
  Atkinson, C., Qiao, F., Yang, X., Zhu, P., Reaves, N., Kulik, L., Goddard, M., Holers, V.M., and Tomlinson, S., Circulation, 1/1/2015
• A new approach for the treatment of arthritis in mice with a novel conjugate of an anti-C5aR1 antibody and C5 small interfering RNA  
  Mehta, G., Scheinman, R.I., Holers, V.M., and Banda, N.K., J. Immunol., 1/1/2015
• A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and...  
  Kulik, L., Hewitt, F.B., Willis, V.C., Rodriguez, R., Tomlinson, S., and Holers, V.M., Mol. Immunol., 1/1/2015
• Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the Women's Health Initiative  
  Mackey, R.H., Kuller, L.H., Deane, K.D., Walitt, B.T., Chang, Y.F., Holers, V.M., Robinson, W.H., Tracy, R.P., Hlatky, M.A., Eaton, C.B., Liu, S., Freiberg, M.S., Tala..., Arth. Rheum., 1/1/2015
• An internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeks  
  Liang, M.H., Couto, M.C., Duarte, C.C., Gall, V., White, P., Naides, S., Schumacher, H.R. Jr., Hwang, A.S., Holers, V.M., Deane, K.D., Gupta, S., Ho, I.C., Finckh, A.,..., Clin. Rheum., 1/1/2015
• Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis  
  Gan, R.W., Trouw, L.A., Shi, J., Toes, R.E., Huizinga, T.W., Demoruelle, M.K., Kolfenbach, J.R., Zerbe, G.O., Deane, K., Edison, J.D., Gilliland, W.R., Norris, J.M., a..., J. Rheum., 1/1/2015
• IgM exacerbates glomerular disease progression in complement-induced glomerulopathy  
  Panzer, S.E., Laskowski, J., Renner, B., Kulik, L., Ljubanovic, D., Huber, K.M., Zhong, W., Pickering, M.C., Holers, V. M., and Thurman, J.M., Kidney Intl., 1/1/2015
• Determinants of mortality among postmenopausal women in the Women’s Health Initiative who report rheumatoid arthritis  
  Kuller, L.H., Mackey, R.H., Walitt, B.T., Deane, K.D., Holers, V.M., Robinson, W.H., Sokolove, J., Chang, Y., Liu, S., Parks, C.G., Wright, N.C., and Moreland, L.W., Arth. Rheum., 1/1/2014
• Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAp44 expression  
  Banda, N.K., Mehta, G., Kjaer, T.R., Takahashi, M., Schaack, J., Morrison, T.E., Thiel, S., Arend, W.P., and Holers, V.M., J. Immunol., 1/1/2014
• Rheumatoid arthritis in the Women's Health Initiative: methods and baseline evaluation  
  Kuller, L.H., Mackey, R.H., Walitt, B.T., Deane, K.D., Holers, V.M., Robinson, W.H., Sokolove, J., Chang, Y., and Moreland, L.W., Am. J. Epidemiol., 1/1/2014
• Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls  
  Young, K.A., Terrell, D.R., Guthridge, J.M., Kamen, D.L., Gilkeson, G.S., Karp, D.R., Ishimori, M.L., Weisman, M.H., Holers, V.M., Harley, J.B., Norris, J.M., and Jame..., Lupus, 1/1/2014
• Deficiency of complement receptors CR2/CR1 in Cr2-/- mice reduces the extent of secondary brain damage after closed head injury  
  Neher, M.D., Rich, M.C, Keene, C.N., Weckbach, S., Bolden, A.L., Losacco, J.T., Patane, J., Flierl, M.A., Kulik, L., Holers, V.M., and Stahel, P.F., J. Neuroinflammation, 1/1/2014
• Clinical utility of complement biomarkers in the diagnosis and treatment of acute thrombotic microangiopathies  
  Yui, J., Holers, V.M., Yang, S., Wu, H.M., and Cataland, S.R., Brit. J. of Haematology, 1/1/2014
• When and where does inflammation begin in rheumatoid arthritis?  
  Demoruelle, M.K., Deane, K.D., and Holers, V.M., Curr. Opin. Rheum., 1/1/2014
• Join now to see all

Books/Book Chapters

• Rheumatology 
  Chapter: Preclinical features of rheumatoid arthritis 
  Holers, V.M., and Deane, K.D.Editors: M.C. Hochberg, A.J. Silman, J.S. Smolen, M.H. Weisman and M.E. Weinblatt.Elsevier, Philadelphia, PA2013
• Rheumatoid Arthritis 
  Chapter: Complement in Rheumatoid Arthritis 
  Holers, V. M.Editors: M.C. Hochberg, A.J. Silman, J.S. Smolen, M.H. Weisman and M.E. Weinblatt.Mosby, Inc., St. Louis, MO2009
• Contemporary Targeted Therapies in Rheumatology 
  Chapter: Complement and pregnancy loss 
  Holers, V.M., and Salmon, J.E.Editors: J.S. Smolen and P.E. Lipsky.Informa Healthcare, Abington, UK2008
• Rheumatology 
  Chapter: Systemic lupus erythematosus: the complement system 
  Page 1243 - 1252Holers, V.M.Editors: M.C. Hochberg, A.J. Silman, J.S. Smolen, M.H. Weisman and M.E. Weinblatt).Mosby, Inc., St. Louis, MOEdition 4th,2008
• Complement and Kidney Disease 
  Chapter: Complement deficient mice as model systems for kidney diseases 
  Page 49 - 63Thurman, J.M., and Holers, V. M.Editors: P. Zipfel.Birkhauer-Verlag, Basel, Switzerland2006
• Structural Biology of the Complement System 
  Chapter: Complement receptor CR2/CD21 and CR2-C3d complexes 
  Page 143 - 160Hannan, J. P., Szakonyi, G., Asokan, R., Chen, X., and Holers, V. M.Editors: J. D. Lambris.Marcell Dekker, Inc., New York, NY2004
• Current Directions in Autoimmunity 
  Chapter: Complement receptor 2 and autoimmunity 
  Page 33 - 48Boackle, S. A., and Holers, V. M.Editors: G. Tsokos.Karger, Basel, Switzerland2004
• Biological Therapy in Rheumatology 
  Chapter: Complement receptors 
  Page 167 - 180Holers, V. M.Editors: J. S. Smolen and P. E. Lipsky.Martin Dunitz, Inc., London, UK2003
• Cecil Textbook of Medicine 
  Chapter: Complement in health and disease 
  Page 233 - 240Karp, D. R., and Holers, V. M.Editors: L. Goldman and D. Ausiello.W. B. Saunders, Inc., Orlando, FL2003
• Current Directions in Autoimmunity 
  Chapter: Role of complement in the development of autoimmunity 
  Page 154 - 168Boackle, S. A., and Holers, V. M.Editors: D. Nemazee and A. N. Theofilopoulos.Karger, Basel, Switzerland2002
• Rheumatology Secrets 
  Chapter: Tolerance and autoimmunity 
  Page 30 - 44Holers, V. M.Editors: S. West.Hanley and Belfus, Inc., Philadelphia, PA2002
• Rheumatology Secrets 
  Chapter: Immunogenetics of rheumatic diseases 
  Page 28 - 38Holers, V. M.Editors: S. West.Hanley and Belfus, Inc., Philadelphia, PA2002
• Clinical Immunology 
  Chapter: Complement deficiencies 
  Holers, V. M.Editors: R. Rich.Mosby, Philadelphia, PA2001
• Clinical Immunology 
  Chapter: Complement 
  Holers, V. M.Editors: R. Rich.Mosby, Philadelphia, PA2001
• Therapeutic Interventions in the Complement System 
  Chapter: Complement as a regulatory and effector pathway 
  Page 1 - 32Holers, V.M.Editors: Lambris, J. D., and Holers, V.M..Humana Press, Inc., Totowa, NJ2000
• Therapeutic Interventions in the Complement System 
  Holers, V.M.Editors: Lambris, J. D., and Holers, V.M..Humana Press, Inc., Totowa, NJ2000
• Principles of Molecular Rheumatology 
  Chapter: Complement 
  Page 145 - 160Holers, V. M.Editors: Tsokos, G..Humana Press, Inc., Totowa, NJ1999
• The Complement Factsbook 
  Chapter: Complement Receptor Type 2 
  Guthridge, J. G., and Holers, V. M.Editors: Morley, B. and Walport, M. L..Academic Press, London, UK1999
• Gout, Hyperuricemia and Other Crystal-Associated Arthropathies 
  Holers, V.M.Editors: Smyth, C.J., and Holers, V. M..Marcel Dekker, New York, NY1998
• Rheumatology 
  Chapter: The Complement System 
  Holers, V. M.Editors: Klippel, J. H. and Dieppe, P. A..Mosby-Wolfe, London, UKEdition 2nd,1997
• Rheumatology 
  Chapter: Complement Deficiencies and SLE 
  Holers, V. M.Editors: Klippel, J. H. and Dieppe, P. A..Mosby-Wolfe, London, UKEdition 2nd,1997
• Manual of Clinical Laboratory Immunology 
  Chapter: Complement Receptors 
  Page 192 - 202Holers, V. M.Editors: Rose, N. R., de Macario, E. C., Folds, J. D., Lane, H. C., and Nakamura, R. M..ASM Press1997
• Principles and Practices of Clinical Immunology 
  Chapter: Complement 
  Page 363 - 391Holers, V. M.Editors: Rich, R..Mosby, St. Louis, MO1995
• Rheumatic Disease Clinics of North America 
  Chapter: Genetics of the complement system and rheumatic diseases 
  Page 893 - 914Moulds, J., Krych, M., Holers, V. M., Liszewski, K., and Atkinson, J.P.Editors: B. Dudlick.1992
• Curr. Opin. Immunol. 
  Chapter: Complement receptors 
  Page 8 - 13Krych, M., Atkinson, J. P., and Holers, V. M.Current Biology Ltd, London, UK1992
• Join now to see all

Lectures

• Amelioration of disease in the MRL/lpr model of lupus by treatment with an anti-C3d monoclonal antibody that blocks C3d:CR2 ligand:receptor interactions 
  Rhodes, Greece - 1/29/2016
• The mucosal hypothesis and the molecular origins of rheumatoid arthritis 
  Seattle, WA - 1/25/2016
• Pre-RA: The evolution of autoimmunity in rheumatoid arthritis 
  Leeds, England - 1/24/2016
• Studies of at-risk populations provide insights into the origins, pathogenesis and prevention of rheumatoid arthritis 
  Tokyo, Japan - 1/22/2016
• Insights into the initiation and preclinical pathogenesis of rheumatoid arthritis from studies of at-risk populations 
  New York, NY, 2016; Chicago, IL, 2016 - 1/17/2016
• Insights from studies of at-risk populations into the initiation and preclinical pathogenesis of rheumatoid arthritis 
  1/1/2016
• Rheumatoid arthritis and the mucosal origins hypothesis 
  Steamboat Springs, CO - 1/1/2016
• Living in the ‘tidal pool’: bridging the gap between academic science and pharmaceutical development 
  Denver, CO - 1/30/2015
• Moving the bar from treatment to prevention of autoimmune disease: the case for rheumatoid arthritis 
  Denver, CO - 1/28/2015
• Characterizing the molecular origins of human rheumatoid arthritis 
  San Diego, CA - 1/25/2015
• Targeting sites of complement activation for imaging and therapy 
  Chicheley, UK - 1/23/2015
• Targeting the complement C3d:CR2 interface for therapeutic and diagnostic purposes 
  Uppsala, Sweden - 1/20/2015
• Rheumatoid arthritis: mechanisms and predictors of pre-clinical RA 
  San Francisco, CA - 1/10/2015
• Pathogenic humoral autoimmunity in the transition to clinically apparent arthritis 
  1/10/2015
• Targeting mechanisms of local complement activation for diagnostic and therapeutic applications 
  Denver, CO - 1/7/2015
• The intersection of genes and environment in the initiation and early development of rheumatoid arthritis 
  San Francisco, CA - 1/6/2015
• The complement system as a target for biologics against autoimmune diseases 
  Boston, MA - 1/5/2015
• Pathogenic natural antibodies: common neoepitopes found acress multiple disease models and use as targeting modules for novel complement inhibitors 
  Chania, Greece - 1/3/2015
• Complement therapeutics come of age: current status and evolving approaches to targeted therapy 
  Irvine, CA - 1/27/2014
• Complement therapeutics (finally) come of age: current uses and emerging opportunities 
  Pittsburgh, PA - 1/23/2014
• Early natural history studies provide novel insights into pathogenesis and opportunities for prevention of rheumatoid arthritis 
  Pittsburgh, PA - 1/22/2014
• Natural history of rheumatoid arthritis: What we learn from studies of at-risk individuals 
  Birmingham, AL - 1/20/2014
• Complement in the pathogenesis of inflammatory arthritis: How animal models inform the new era of human therapeutics 
  Birmingham, AL - 1/20/2014
• Rheumatoid arthritis; Preclinical natural history studies provide key insights into disease initiation, pathogenesis and prevention 
  Birmingham, AL - 1/19/2014
• Studies of the etiology of rheumatoid arthritis: a multi-disciplinary approach 
  Denver, CO - 1/10/2014
• Join now to see all